- NewsCategory：
- All Company news Industry news
common105One result
-
0929
Catabasis Pharmaceuticals and the Jain Foundatα✔≠®ion Announce a Preclinic₽€≈σal Research Collaboration to Study £✔₩Edasalonexent in Dysferlinopathy
Catabasis Pharmaceutic™≈δ★als, Inc., a clinical-stage biopharmaceutic'>&al company, and the Jain Founda®♠tion, a non-profit foundation whosα¥e mission is to cure muscular dystrophies caused ≈π¥₽by dysferlin protein deficien≥₽÷cy, announced a preclinical research c§♠ollaboration to study edasalonex₹ ent (CAT-1004) in Dysferlinopathy. Dysferli✘<nopathy (Limb-girdle mu>$₩✘scular dystrophy typ↔≤±e 2B / Miyoshi myopathy) is a serious"λ' rare disease that causes progres λ∏sive muscle weakness for which t✔¶here are currently no approved trea→≠tment options. Edasalonexent is in P®÷α→hase 3 development for the trea≤↓tment of Duchenne muscular dystrπ'✘∑ophy (DMD) and has the potenti÷λal to benefit patients with other diseases, ↕ ≤€such as Dysferlinopathy.In Dysferlinopathy, muscl ₹δes lack dysferlin and as a result NF-kB is chr♥≥onically activated. Edasalonexent,£¶ an oral small molecule designed to inhib≠←λit NF-kB, has the po€•πtential to slow disease €αδ"progression in dysferlin-deficie•nt populations. Under this colla↑boration, Catabasis and the Jain Foundation are®¥® conducting a preclinical s$←tudy to evaluate the potential ★ of edasalonexent as a the&λ§₽rapeutic intervention for D∞≠ ≠ysferlinopathy by mea•ΩΩsuring disease progressio§©¶n in dysferlin-deficient m ∑™÷ice treated with edasalonexent. The study±σ≤ will utilize magnet→±ic resonance imaging (MRI) and magnetic reson↓¥ance spectroscopy (MRS) Ω>₹σto measure muscle volume, fat acc≈™umulation, and other changes in the dysferlin-™∏λ♠deficient mice. Initial results are expected in ™≤φ§the first half of 2020.“We look forward to ∞✔γworking with Catabasis to advance re₽€€≈search for Dysferlinopathy,” said Laura Ru$♦fibach, Ph.D., and Doug <Albrecht, Ph.D., Co-Presidents o♠δ✔f the Jain Foundation. “Patients with Dysferl↔≈&inopathy (LGMD2B / Miyoshi myopathy) experienc≤&e a progressive and deb≈≈ilitating decline in m→©λ∑uscle function which signif∑≠♣icantly impacts their lives. As there are cσ≠₽urrently no treatment options, we λ♦✔"are excited to explo€±¥ re the potential of edasalonexent to benefit thosπ↓e living with this disease.”“The chronic§π activation of NF-kB is a key driver in ma₹≈≈ny neuromuscular disorders, ββincluding Duchenne muscular d↓©ystrophy. Evidence of NF-kB activation in÷β≤ Dysferlinopathy suggests ←•÷§a similar disease mechanism and opportunity for∏ intervention. In the Mo♦←veDMD trial and open-label ext∑♥¥ension, treatment with edasa∏<$lonexent slowed disease p¥↕rogression compared to t∑€he off-treatment control period. Through this co&$llaboration, we look forwa> ∏rd to learning more about the δ∑∏€potential of edasalonexent in Dys÷§ferlinopathy, where, similar to Duchenn±<e, there is also a significant unmet n♦÷λeed,” said Andrew Nichols,ασ Ph.D., Chief Scientific Officer at Catabasi>₽<s Pharmaceuticals.information source:pharma↕§ focus AsiaThe original link:https:https://wwwδ←.pharmafocusasia.com/news/catabasis-phar₹↕§★maceuticals-and-the-jain-f§₩≤oundation-announce-a-preclinical-research-colla∑×£boration-to-study-edasalonexent>γ₹-in-dysferlinopathy2019 Asia-pacifi"™βc pharma IP Leader S✔γ≤≥ummit: http://en.zenseegroup.co✘σ§m/p/404716/ will be held in Beijiα↕ ng on November 14-1÷£↓5, and will attract more than÷ & 500 industry experts fro™↑m domestic and forei•δgn pharmaceutical companies,&₹¶ biotechnology companies, governments, asso≥'ciations, law firms, intell↕σectual property agents and other compan∞↓£₹ies to attend.Official registration and consultation channels:Contac↑✔t：AnnPhone: 021-65650305Email：Marketing@z™←×enseegroup.comhttp://en.zenseegroup.com/p/510934∑≤™/ -
1008
Prometheus Biosciences, Inc., Enters Into M ♦✘≥ulti-Target Strategic Collabor₹©£ation with Takeda to Develop Targeted Therap€¶₹γies for Inflammatory Bowel Disease
Prometheus Biosciences, Inc., a biopharmaceutical↕φ company committed to the discov↑↔ery, development, and commercialization of© ₽ a broad portfolio of novel pr↓₽'ecision therapeutics and com↓≈panion diagnostics for patienδε↔ts living with unmet needs in gastroen•λterology and autoimmune dise±₩ases, announced that it has entered into a globa"¥l, multi-target strategic ♠§↔collaboration with T≠↕akeda Pharmaceutical Company Limited (Take× da) to discover, develop, and ≤φ₹commercialize novel therapies for inflammator™¶y bowel disease (IBD). The collaboration combin™>¥es the proprietary bioinformatics discovery pl¶<☆×atform and companion diagnostic tools develop •★ed by Prometheus Biosciences with Takeda's•♠≈✘ expertise in gastroenterology♥∑ and drug development, in ₽↔≈order to discover and advλ₩αance up to three targeted IBD therapα∏♥∏eutics and companion diagnosδ÷≥tics. Prometheus Biosciences will be r♠→™esponsible for the identification and validat↓&ion of three unique dru'λg targets for IBD, along with the develoγ¥pment and commercialization of c ∞ompanion diagnostics to complement the targe£π>ted drugs. Takeda will be responsible☆→σ¥ for all drug discovery, clinical d 'evelopment, and commercialization ££activities for the resulting targe₹←ted therapeutics."We are impressed ★★αΩwith Takeda's commitment to developing a portfo≈lio of therapies to address all IBD patients, esp✔∑ecially those with unmet needs," said Mark M cKenna, chief executive officer, Promethe↔∑us Biosciences. "We believe that a t argeted, precision meβ₽±Ωdicine approach is needed to deliver new, eff™↕"ective therapeutic options in inflammatoΩ "<ry bowel disease. Through ®our partnership, we are excited $φ$¶to combine the Prometheus bioinf←→<ormatics platform and advanced machine∑δ< learning techniques with Takeda's expert♣∑♣↔ise in drug development to deliver a newσ¥↕ generation of IBD therapies."Und¥"λλer the terms of the agreement, Pr×∞ometheus Biosciences♣ε will receive an undisclosed initiα al upfront payment from Takeda and is el••igible to receive up to $420M ≥$in development, regulatory, and commercialγ< milestone payments, in total, across all three ♥≈ programs. In addition, Prometheus Bioφ©sciences is eligible to receive royal÷βty payments on global comme•rcial sales from each pro✔∏↔gram.information sourσ•ce:pharma focus AsiaThe original link:ht § tps:https://www.pharmafo♥↔≠cusasia.com/news/prometheus-≈×biosciences-inc-enters-into-mult☆♥αi-target-strategic-collaboration-$ with-takeda-to-develop-↕✔×targeted-therapies-for-inflaσ↕mmatory-bowel-disease2λ∏♠$019 Asia-pacific pharma Iδ←≤P Leader Summit: htt♥®₽•p://en.zenseegroup.com ®/p/510934/ will be held in Beij§&<ing on November 14-15, a♠≤£nd will attract more than ∏¶→500 industry experts from domestic and f↑←π"oreign pharmaceutical companies, biotechnλ ology companies, governments, associa× tions, law firms, intellectual property agents an∑¥d other companies to attend.Official re☆→αgistration and consultation channels:Cont $act：AnnPhone: 021-65650305Email：Markπ≠eting@zenseegroup.comhttp://en.zenseegroup×↔₹.com/p/510934/ -
1009
Goldfinch Bio Announces Licensπ®✘≈ing Agreement with Takeda f Ωor CB1 Monoclonal An¥< βtibody for the Treatment of Rare and Metabolic Ki€≠dney Diseases
Goldfinch Bio, a U.S.-based, clini✘ε'↕cal stage biotechnology company focused on disc€ ≤€overing and developing prλ®ecision medicines for the treatment ♦"® of kidney diseases, today announced it &§entered into a license agreement with Takγ↕eda Pharmaceutical Company L≥σ✔®imited (“Takeda”) for worldwide rights to a preππ$clinical, peripherally-restricte→≈÷¶d cannabinoid receptor 1 (CB1) monoclonal ←≠antibody. Goldfinch Bio £♥ will assume all development and comm♠♥π&ercialization responsibilities for the πλ£₽treatment of rare and metabolic kidney d•&iseases worldwide. However, the ↓ 'agreement grants Takeda the option, prior to♦♦↓ the initiation of pivot&∏al studies, to reques≤§¥t Goldfinch Bio negotiate with Takedφ≈₽ a for sub-licensing of Japanese rights t↔λ$λo Takeda. Financial terms of theβ agreement were not disclosed. Goldfinch Bio™✘δ plans to file an investiga♥¶✔±tional new drug (IND) application for this CB1 δδinhibitor, re-named GFB-024, in the second halφ←™f of 2020.“In recent years, our unde ♦rstanding of the role of CB1 sigΩ naling in exacerbating progressive kidneβ✘γ✔y diseases has grown subst₩ antially. In this context, a monoclon♠Ωal antibody directed toward thπγ≠e CB1 receptor is potentially well-suited to el₽icit the beneficial pharmacology asso§¶↔ciated with the periphe→₹γral inhibition of the CB1 rec§∞eptor,” said Anthony John≥↕≈son, M.D., President and Chi ef Executive Officer of Goldfinch Bio. “Gα ↔↓oldfinch Bio will deploy its biology platform a ←nd Kidney Genome AtlasT∏αM to develop this therapeutic agent ε♥♠in subsets of patients wi"₩ th kidney diseases most likely to pr₩¥eferentially respond to CB1 inhibition. With GF£±♣×B-887, our TRPC5 inhibitor for FSGS, in Phase☆σ♣ 1 clinical development, this per"↕<ipheral CB1 inhibitor will be t↑♥☆he second clinic-ready pro€♦gram in Goldfinch Bio’s $♣®≥pipeline. We look forward to collab€→εδorating with Takeda on this program.”“Gα¶oldfinch Bio is ideally suited&≈↑≠ to advance development of this✔♣≈ program,” said Dan Curran, M.D.↕≠©, SVP and Head, Rare Di$®♣seases Therapeutic Area Unit, Takeda. “Th☆γγe application of its p→♣recision medicine approach, froε✔m candidate target validation throughφ£ to identification of potential treatme♠'¶nt-relevant subgroup₩↑s, is unique in the deve↓↕♣←lopment of chronic metabolic kidney disease tr ∑∑eatments.”Preclinical data support the inhibiti©♦on of CB1 signaling as ↓σa novel treatment of Diabetic Nephropathy (DN) ∏↓βand obesity-related glomerulop∞₩σ€athies (ORG), given th←♣±e potential metabolic benefits and direc≠€↔t effects on the kidney to preven'Ωσ•t fibrosis and preserve kidney function. DN devδσ σelops in 30 to 40 percent of pa✔tients who have diabetes and is a l↕•γeading cause of morbidity, mortality £≈and end-stage kidney disease in the Unite÷δ€∑d States and worldwide. O™γ↑≈RG is a rare kidney d≈✔∏isorder characterized by sigε∏•™nificant proteinuria and progressive renal d♥↓≈ysfunction. Although both DN and OR β¥≥G are increasing in prevalence in≠♦ parallel with the obesity epidemi↓₹♣∞c, well-established diseas±$e modifying therapies are lacking. Goldf&₹↔βinch Bio plans to initiate a phase 1 stud∑↓₹y for GFB-024 in 2H 2020.infor↔÷≈mation source:pharma focus AsiaThe origina≥★l link:https://www.pharmafoc∏λ<usasia.com/news/goldfin ∑ch-bio-announces-licensing-agreement-∞€σwith-takeda-for-cb1-monoclonal-antibodyΩ"→σ-for-the-treatment-of-rare-and-metabolic-kidneyσ←§-diseases2019 Asia-pacific pharma IP Leade☆α"$r Summit: http://en.zenseegroup.com/p/404716/&₩₩≠₽nbsp;will be held in Beijing&nbs←≤¥p; on Nove>πmber 14-15, and will attract more thaπ₹↑Ωn 500 industry experts from domesti&→∞♥c and foreign pharmaceutical companies,¶ biotechnology companies, governme×↓nts, associations, law firms, intellectual prop•÷erty agents and other companies ∑to attend.Official registration and con∞€•™sultation channels:Cont₽×act：AnnPhone: 021-65650305Emai₩λl：Marketing@zenseegroup.comhttp://en.zenseegrou♠£×p.com/p/510934/ -
1010
4D Pharma collabor4D Pharma collaborates wi¶↓±th MSD to develop live biotherapeutic ₹±≤±products for vaccinesates with MSπ±$©D to develop live bio¶©therapeutic products for vaccines
4D pharma plc, a leadi≥↑ng pharmaceutical co"∏mpany in the developm¶♣♣•ent of live biotherapeutics, today ≈₽><announces that the company has entered into a♣π™& research collaboration agreement and ₩©an option license to use with MSD (tradi♥≈↕ng name of Merck & ¥✔"£Co., Inc., in Kenilworth , New Jersey , United βπφStates of America) to Discover and∑¥ Develop Live Biotherapeutic Products ("π β"LBP") for vaccines.Under the terms o§<αλf the agreement, MicroRx®>ε♦×, the proprietary platform of 4D, ✘§∞will be associated with MSD's expertise in the de☆£ velopment and commercialization of new vaccines, ≤≠in order to discover and develop LPBs as ±♠vaccines in maximum three undi♣sclosed indications. 4D has the rig φ¥∑ht, subject to certain conditions, to purc↕>Ωhase from MSD for $ §×≤5 million common shares o§€f 4D during the first 12 monthφΩ≈s of the collaboration. In®≤ addition to an initiaπ ≥l cash payment, for each indication, 4D will b☆α↑'e eligible to receive up∞♠±≈ to $ 347.5 million in exercise of options a→★γnd regulatory and developmen☆←t milestone payments, as ¥¥well as royalties the a↓☆∏nnual net sales of any licensed producφ™t resulting from the collabo←≈±ration.Duncan Peyton ±λ, CEO of 4D, said, "This collaborative researc&₩≥h agreement brings together 4D's i£§εnnovations in the microbiomeαπ∏£ field and MSD's track record in th≤&♥e development of advanced vac↔αcines. MSD and 4D worke Ωd closely together combining world-class scientif¶₩ ☆ic knowledge to develop a wor♠¶$ k plan to advance understanding of∑• this field, with the goal of generat&§✘÷ing a new class of vaccines in areas whπ∑<ere unmet needs are important.₹™ "Daria Hazuda , Scientific ≤ε∑Director of MSD's Exploratory Science Cσ↔enter and Vice President of Reδφ™©search on MSD's Infectious Diseases₩©♣ and Vaccines Discovery, said, "A kγ∏ey element of our goal at the Center for♥&↕ε Exploratory Science•÷ is the assessment of§¥ emerging areas of emerπ$ging biology that are likely to have a maβ★jor beneficial impact on hu∞♦man health. By applying MicroRx® technology of 4D¥, we hope to obtain useful informα✔ation on the role of the host microbiome inπ♥ modulating the immune response and, ↓↔↔"ultimately, the protect ♣♥ion conferred by vaccines. "information sλ&≥♣ource:pharma focus AsiaThe original link:https:htσ™ε&tps://www.pharmafocusa•←£∑sia.com/news/4d-pharma-colla'σborates-with-msd-to-develop-live-biothera₽"peutic-products-for-vaccine'™s2019 Asia-pacific pharma IP Leader Summit"÷: http://en.zenseegroup.com/p/510934<•☆/will be held in Beijing on♥Ω November 14-15, and will attract more ∑σ≠×than 500 industry experts from domestic an♦£✘←d foreign pharmaceutical companies, biotechnolo♦™gy companies, governments, associations, law fi≥δ&>rms, intellectual property agents and other compa£→nies to attend.Official registration and consult₩¥πation channels:Contact：AnnPhone: 021-65650♣★305Email：Marketing@zenseegroup εγ€.comhttp://en.zenseegroup.c↔¶✔↔om/p/510934/ -
1011
Viela Bio Enters Strε ategic Collaboration with Mitsubishi Tanabe Pβ∞÷Ωharma to Develop and Commercialize÷↑∑ Inebilizumab for Autoi♠¶mmune Diseases in Japan and Other Asia ↔♦Regions
THURSDAY, OCTOBER 10, 2019Viela Ω≈Bio, Inc. and Mitsubishi Tanabe Pharma Corporati¥¥on (“MTPC”) today announced a collaboration"®™→ focused on the development ★ ☆πand commercialization o<∑f inebilizumab – Viela’s humanized anti-C₩δ€D19 monoclonal antiboπ©≈±dy – in nine Asia regions for neuromyeli★™®®tis optica spectrum disorder§ σ> (NMOSD), as well as★' other potential future indications.♠¶•“This partnership adds to our ability to com ♠✘←mercialize inebilizu& &↑mab globally, subject to π&™regulatory approval,” commented Bing Yao, Phφ€✘€.D., Viela’s Executive Chairman and Chief Exec₹γ₽utive Officer. “As a well-established pharmaceut$¶€ical company in Japan, Mits>↔• ubishi Tanabe has strong product de>™velopment and commercialization capabilities in A₽φ±®sia, and we believe, i↔ €s an ideal partner for expanding inebilizumab←¥∑≤’s potential reach to thousands of additionalλ∑☆ patients in need of viable treatments, with ♠βNMOSD as an initial indication.”Under term♣← s of the collaboration, Viela will rδ€eceive an up-front lic≥$$✔ensing fee of $30 mi★&₽llion as well as additional payments contingent€→α on certain development and commercial ∑"♣milestones, plus paymenα£γ÷ts based, in part, on λ∞sales revenue. MTPC will ←be responsible for leading development and commer★∞cialization of inebilizumab ≥λ$in Japan, Thailand, ✘≥φSouth Korea, Indones®ia, Vietnam, Malaysia, Philippines, Singapore→♣§, and Taiwan.“Our organization is deφ Ωlighted to partner with Viela to develop a"&nd commercialize their promising product ±¥candidate inebilizum&φ£☆ab for autoimmune and™ ≥♠ inflammatory diseases,” said Masay&¶δ€uki Mitsuka, MTPC President & Representativε♥e Director. “Inebilizumab is an exciting "↔product candidate tha♠€t, based on the results f₽↕•rom the N-MOmentum pivotal study, &is well-positioned to provide meaningful₩×£ benefit for patients with Nγ¶★MOSD, and potentially addit ®∏ional diseases, subj✔λect to regulatory approval. We are excit✘λλ<ed to work with Viela tφσ≥o advance inebilizuma> ₽£b in Japan and other Asia regions, aσδ€nd look forward to a producti<'ε ve partnership between our co§±mpanies.”The U.S. Food and∏φ Drug Administration↓¥• (FDA) recently accepted for review Viela’s☆→✔ Biologics License Application (BLA♥α ) for inebilizumab for the treatme">£≥nt of NMOSD. information source:pharmβ ✘ a focus AsiaThe original link:https:https:©σ≥×//www.pharmafocusasia.com/news/δ✘&viela-bio-enters-strategic-collaboratioφ₩£¶n-with-mitsubishi-tanabe-pharma-to-de →✔velop-and-commercialize-inebilizumab-fo•• r-autoimmune-diseases-i☆®∏n-japan-and-other-asia-regions2019 Asia-pa≥>cific pharma IP Leader Summit: http://en.zenseegr∏×←oup.com/p/510934/will be held in Be"≤™ijing on November 14§σ↓-15, and will attract more than 500 i<£↓¥ndustry experts from domes☆tic and foreign pharmaceutical companies, biotech¥₹®¶nology companies, governments, associations,←≤ law firms, intellectual property agents±" and other companies ®β¶∑to attend.Official registra↑&✔tion and consultation chan₩→nels:Contact：AnnPhone: 021-65650305Email&≥↑：Marketing@zenseegroup.comhttp://en.zenseeg↕₩roup.com/p/510934/
Contact Us
Zensee_Daystar online
© 2011-2016